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ABSTRACT
Introduction The IMPACT study focuses on chronic low 
back pain (CLBP) and depression symptoms, a prevalent 
and complex problem that represents a challenge for 
health professionals. Acceptance and Commitment 
Therapy (ACT) and Brief Behavioural Activation Treatment 
for Depression (BATD) are effective treatments for patients 
with persistent pain and depression, respectively. The 
objectives of this 12 month, multicentre, randomised, 
controlled trial (RCT) are (i) to examine the efficacy 
and cost- utility of adding a group- based form of ACT 
or BATD to treatment- as- usual (TAU) for patients with 
CLBP and moderate to severe levels of depressive 
symptoms; (ii) identify pre–post differences in levels of 
some physiological variables and (iii) analyse the role of 
polymorphisms in the FKBP5 gene, psychological process 
measures and physiological variables as mediators or 
moderators of long- term clinical changes.
Methods and analysis Participants will be 225 patients 
with CLBP and moderate to severe depression symptoms 
recruited at Parc Sanitari Sant Joan de Déu (St. Boi de 
Llobregat, Spain) and Hospital del Mar (Barcelona, Spain), 
randomly allocated to one of the three study arms: TAU vs 
TAU+ACT versus TAU+BATD. A comprehensive assessment 
to collect clinical variables and costs will be conducted 
pretreatment, post- treatment and at 12 months follow- up, 
being pain interference the primary outcome measure. 
The following physiological variables will be considered at 
pretreatment and post- treatment assessments in 50% of 
the sample: immune- inflammatory markers, hair cortisol 
and cortisone, serum cortisol, corticosteroid- binding 
globulin and vitamin D. Polymorphisms in the FKBP5 
gene (rs3800373, rs9296158, rs1360780, rs9470080 
and rs4713916) will be analysed at baseline assessment. 
Moreover, we will include mobile- technology- based 
ecological momentary assessment, through the Pain 
Monitor app, to track ongoing clinical status during ACT 
and BATD treatments. Linear mixed- effects models using 
restricted maximum likelihood, and a full economic 
evaluation applying bootstrapping techniques, acceptability 
curves and sensitivity analyses will be computed.
Ethics and dissemination This study has been approved 
by the Ethics Committee of the Fundació Sant Joan de 
Déu and Hospital del Mar. The results will be actively 
disseminated through peer- reviewed journals, conference 
presentations, social media and various community 
engagement activities.
Trial registration number NCT04140838
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INTRODUCTION
Recent systematic reviews have estimated that more 
than 10% of the general population worldwide suffers 
chronic pain.1 2 Among chronic pain conditions, chronic 
low back pain (CLBP) is one of the most prevalent and 
costly.3 4 Depression is by far the most common psychi-
atric problem associated with CLBP.5 6
The relationship between pain and depression is bidi-
rectional.7 Some theories postulate that pain and depres-
sion share common physiopathological mechanisms 
and that one can lead to the other via activation of these 
mechanisms. This could include mediators of the inflam-
matory and immune response and the role they play in 
endogenous nociceptive regulation and affective regu-
lation.8 In particular, cytokines appear to have a crucial 
role in chronic pain conditions, so that a high expression 
of proinflammatory mediators can alter the physiopa-
thology of chronic pain.9 At the same time, inflammatory 
mediators of innate immunity and cell- mediated immu-
nity cooperate in the onset and expression of depres-
sion.10 On the other hand, a clear correlation between 
vitamin D deficiency and the presence of chronic pain 
and depression has been described in recent years.11 
Vitamin D substantially modulates the inflammatory 
response by controlling cytokine expression, inhibiting 
proinflammatory, and increasing anti- inflammatory ones. 
Vitamin D deficiency could affect the response of patients 
with chronic pain to the treatments applied.12–15
Chronic stress appears to play a pivotal role in mental and 
physical health and leads to hypothalamic–pituitary–ad-
renal axis (HPA) dysregulation which in turn impairs the 
stress response.16 17 Genetic, epigenetic and early stress 
exposure, among other factors, shape individual resil-
ience and vulnerability, as well as HPA activity.18 19 In this 
regard, the FKB506 binding protein 51 gene (FKBP5) is a 
critical regulator of glucocorticoid receptor activity (and 
thus HPA function too) and its interaction with distal and 
proximal stressors has not been previously examined in 
comorbid chronic pain and depression. This interaction 
could be key for understanding the etiological mecha-
nisms involved in such conditions, as well as for identi-
fying potential therapeutic mechanisms.20–26 In addition, 
hair cortisol reflecting long- term HPA activity has recently 
emerged as a potential predictor of treatment response in 
anxiety and depression.19
The therapeutic options available for chronic pain 
management are very extensive. Interestingly, a number 
of psychological treatments have shown positive effects 
at the psychological, neuroendocrine and immune levels 
in a wide range of pain- related conditions, as well as for 
depression.27 These generally comprise forms of Cogni-
tive Behavioural Therapy (CBT), including treatments 
that focus on mindfulness, and Acceptance and Commit-
ment Therapy (ACT). In a meta- analysis of 11 clinical 
trials in patients with chronic pain,28 ACT was better than 
the control conditions in improving pain acceptance, 
functional impairment, anxiety, depression and pain 
intensity. In addition, another form of CBT, Behavioural 
Activation Treatment for Depression (BATD), has proved 
to be as effective as classical CBT in reducing depressive 
symptoms in a meta- analysis.29
Both treatments, ACT and BATD, are potentially cost- 
effective for the management of chronic pain and depres-
sion, respectively, according to a recent systematic review 
carried out by the team of the present project.30 In our 
opinion, it is important to demonstrate their cost- utility 
for the management of a complex problem as relevant 
as comorbid CLBP and depression, to characterise the 
psychological and physiological mechanisms through 
which they exert their therapeutic effect, and identify 
potential predictors of treatment response.
The objectives of the IMPACT (Improving Pain and Depres-
sion with ACT and BATD) study are (i) to examine the efficacy 
and cost- utility of adding ACT or BATD to treatment- as- 
usual (TAU) in the management of patients with CLBP 
and moderate to severe depression for improving pain 
interference (primary outcome) and depressive, anxious 
and stress symptoms, pain catastrophising and quality of 
life (secondary outcomes); (ii) to identify pre–post differ-
ences in levels of different physiological variables (immune- 
inflammatory markers, hair cortisol and cortisone, serum 
cortisol, corticosteroid- binding globulin (CBG) and 
vitamin D) and correlate these changes with those observed 
at self- report measures and (iii) analyse the role of polymor-
phisms in the FKBP5 gene, psychological process measures 
and physiological variables as mediators or moderators of 
long- term clinical changes.
METHODS AND ANALYSIS
Trial design
The RCT protocol has been developed following the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials.31 For reporting, we will follow the 
Strengths and limitations of this study
 ► This is thought to be the first study comparing the efficacy and cost- 
utility of Acceptance and Commitment Therapy and Behavioural 
Activation Treatment for Depression in addition to treatment as usu-
al (TAU) versus TAU alone for the management of comorbid chronic 
low back pain (CLBP) and depression.
 ► The IMPACT protocol combines assessment with classical legacy 
measures and ecological momentary assessment to obtain more 
precise information on the dynamics of the variables to be assessed.
 ► Besides self- report measures, this study will include physiological 
variables such as cortisol, cytokines and vitamin D levels, in order 
to know the impact of treatments on these stress- related biological 
variables.
 ► As far as we know, this study represents the first attempt to explore 
the predictive role of FKBP5 gene and distal or proximal stressful 
experiences in response to psychological treatments for CLBP and 
depression.
 ► Blinding of patients and therapists will not be possible. This rep-
resents a fundamental problem in randomised controlled trials with 
psychological treatments.
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guidelines of the Consolidated Standards of Reporting 
Trials (CONSORT)32 and the Consolidated Health 
Economic Evaluation Reporting Standards statement.33 
IMPACT is a 12- month multicentre RCT with three treat-
ment arms: TAU, TAU+ACT and TAU+BATD. Therefore, 
patients in three arms will receive TAU, and ACT and 
BATD will be complementary treatments to the standard 
one provided in the Spanish National Health System.
Recruitment strategy
Potential participants are those patients with CLBP diag-
nosis seeking services currently or in the last 3 years at 
Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, 
Spain) or Hospital del Mar (Barcelona, Spain). These 
patients will be screened to evaluate their current pain 
intensity and the Patient Health Questionnaire (PHQ-9) 
will be administered to confirm the presence of moderate 
to severe active depression.
Sample size
Sample size was estimated considering a target power 
of 80%, an alpha level of 0.05 and was calculated taking 
the primary outcome measure into account (Brief Pain 
Inventory- Interference Scale (BPI- IS)). The estimate 
was based on a one- way analysis of variance (followed 
by Dunn–Bonferroni post- hoc tests) for between- group 
differences in the change from baseline to subsequent 
assessment, assuming no systematic baseline or other 
covariate group differences after randomisation. The 
minimal clinically significant difference for the BPI- IS is 1 
point (SD of improvement of 2 points).34 This calculation 
yielded a suggested sample size of 64 patients per study 
arm. Allowing for a potential attrition rate of 15% our 
final sample size was 75 participants per group.
Eligibility criteria
All participants will meet the following inclusion criteria: 
male or female aged 18–70 years; diagnosis of CLBP (>3 
months) according to medical history; pain intensity >4 
points out of 10 points on a numeric pain rating scale in 
the past week; moderate to severe depressive symptoms 
according to PHQ-9 (total score ≥10); fluent in Spanish 
language and provision of written informed consent to 
participate (a copy of the consent form is provided as an 
(online supplementary document). Only participants 
with a score of at least 60% on the question ‘Which situ-
ation describes your pain over the past 4 weeks the best? 
100% of the pain in the low back; 80% of the pain in 
the low back and 20% in the leg(s); 60% of the pain in 
the low back and 40% in the leg(s); 50% of the pain in 
the low back and 50% in the leg(s); 40% of the pain in 
the low back and 60% in the leg(s); or 20% of the pain 
in the low back and 80% in the leg(s)’ will be included. 
With this question, we will be able to differentiate domi-
nant leg pain from dominant CLBP, avoiding the likeli-
hood of recruitment of participants suffering dominant 
radiculopathy.35
Potential participants will be excluded according to the 
following exclusion criteria (based on previous RCTs):36 
the presence of cognitive impairment; previous (last year) 
or current psychological treatment; presence of severe 
psychiatric disorder (eg, psychotic disorder), substance 
dependence/abuse or presence of degenerative medical 
disease (eg, Alzheimer’s dementia); patients involved in 
litigation with the health system; patients with scheduled 
surgical intervention or other interventions and inability 
to attend group treatment sessions. For the biomarkers 
substudy (50% of patients in each study arm), the 
following exclusion criteria will be added: cold/infection 
symptoms on the day of blood collection; needle phobia; 
BMI>30 kg/m2 or weight >110 kg; consumption >8 units 
of caffeine per day (maximum one drink with caffeine on 
the day of testing); smoker >5 cigarettes a day; hair length 
<3 cm, use of glucocorticoid medication or anticytokine 
drugs and being pregnant or breastfeeding.
Procedure and randomisation
A list of potential participants (with contact telephone 
number) will be presented to the study team at each centre. 
This list will pass to the clinicians, so that they carry out 
the telephone screening and set an appointment for the 
first face- to- face interview (performed by health psychol-
ogists) with all those who agree to participate and meet 
the eligibility criteria. After obtaining informed written 
consent, the evaluators will conduct the baseline inter-
view using battery of computer- administered measures. 
Patients will be contacted again after 3–5 days to obtain 
peripheral blood and hair samples. These extractions will 
be performed at a preset time (8.00–9.00 AM) to reduce 
circadian variability in the levels of the immune and endo-
crine markers evaluated. In order to limit the effects of 
medication on the study variables, patients will be asked 
to refrain from taking analgesic or anti- inflammatory 
drugs within 72 hours prior to obtaining the biological 
samples.
Random assignment of participants to study arms will 
be executed after baseline assessments as recommended 
by the CONSORT guidelines.32 Randomisation will be 
planned and executed by a statistician with no involve-
ment in screening, enrolment or treatment processes. 
Once written consent and baseline assessment have been 
completed, study participants will be given a unique 
personal code and randomised by means of an online 
randomisation programme. The computer- generated 
randomisation will apply a permuted block design to 
ensure that the groups are balanced taking biomarkers 
substudy eligibility criteria into account. The randomi-
sation list will remain with the clinical trials committee 
of Fundació Sant Joan de Déu (FSJD) for the full dura-
tion of the RCT. This list will be stored in an encrypted 
file on a password- protected computer in the clinical 
trials supervisor’s office to assure concealment of alloca-
tion. Participants’ assignments will be communicated to 
administrative personnel of each centre by the clinical 
trials supervisor via e- mail. Patients will be informed of 
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their group allocation by the administrative personnel, 
who will send a notification in sealed, opaque numbered 
envelopes.
Two subsequent face- to- face assessments will be carried 
out at the end of the 8 weeks of treatment (post- treatment) 
and at 12 months follow- up (56 weeks after randomisa-
tion). To obtain the biological samples at post- treatment, 
the same procedure as in the baseline assessment will be 
followed. See figure 1 for patients’ flow chart.
Treatments
Treatment-as-usual
In Spain, chronic pain management is mainly carried out 
by general practitioners (GPs) in regular consultations, 
commonly consisting of face- to- face visits (5–10 min) to 
monitor the physical and emotional status of the patient. 
GPs usually provide advice, and prescribe pharmaco-
therapy (pain medications, hypnotics and antidepres-
sants) or make onward referrals to pain units in hospitals 
when more specialised pain management procedures are 
required. The frequency of consultations is based on the 
type and stage of disease of each patient. For this study, 
usual care will be the same as in routine daily practice, 
without any modifications.
Treatment-as-usual+Acceptance and commitment therapy
The ACT treatment component includes, as the 
name implies, methods to promote acceptance (non- 
avoidance) of unwanted experiences, and engagement 
in goal- directed and values- based action. Alternatively, 
ACT is focused on promoting psychological flexibility, 
or the ability to develop behaviour patterns open, aware 
and engaged37 (see table 1). Patients suffering from pain 
recurrently use avoidance as a coping strategy, and at its 
most basic level, this therapy is designed to address that 
by providing a broader set of skills. There is now consid-
erable evidence for the therapeutic model underlying 
ACT38 and for the treatment approach itself as applied to 
chronic pain. Recent meta- analyses supported the effec-
tiveness of ACT in patients with chronic pain.28 39
Treatment-as-usual+Behavioural activation treatment for 
depression
BATD is based on the application of learning principles 
to the pattern of withdrawn or reduced behaviour activity 
associated with depression (see table 2). Its objective is to 
counteract depressive symptoms and, as a consequence, to 
ensure that patients regain a productive and emotionally 
satisfying life. Its methodology essentially consists in ‘acti-
vating’ subjects with depression through programming 
Figure 1 Flowchart of the IMPACT study based on the Consolidated Standards of Reporting Trials guidelines. ACT, 
Acceptance and Commitment Therapy; BATD, Brief Behavioural Activation Treatment for Depression; CLBP, chronic low back 
pain; EMA, ecological momentary assessment; ITT, intention- to- treat; TAU, treatment as usual.
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and conduct of behaviours that are likely to increase the 
experiences of directly positively reinforcing qualities 
in their current context. A meta- analysis supported the 
effectiveness of behavioural activation in patients with 
depression.29
Both psychological treatments (ACT and BATD) will 
be administered in a group format of 8 weekly 1.5 hour 
sessions. In RCTs of psychological treatment, it is recom-
mend that more than one therapist deliver each treatment 
to create a more realistic and generalisable impression of 
Table 1 Outline of ACT group treatment sessions
Session ACT
1 Participants’ and clinician’s presentation. Psychoeducation and introduction to ACT (ACT basics; scientific 
advances in chronic pain and depression management; psychological theories of pain, suffering and stress; 
stressors, fears and indicators; identification of values; breathing exercises).
2 Value analysis I. Problems of experiential avoidance. Creative hopelessness through metaphors: control is the 
problem and not the solution. Anxiety, fight and flight, and its effects. Accepting the risk of the life’s journey: 
experiences, feelings and emotions.
3 Value analysis II. Objectives. Laws of thought and consequences of language. Mind and deactivation of thought 
(cognitive defusion): creating distance with thoughts. Learning meditation techniques and effects. Practicing 
meditation exercises.
4 Value analysis III. Psychological barriers and obstacles. Emotional distress and its consequences. Emotional 
phenomena, personality variables and health states. Discovering commitments with committed actions.
5 Values and feelings. Taking the initiative with a ‘Plan of action and willingness’. Psychological flexibility, resilience 
and self- motivation. Expansion and body scan exercises. Learning to relax.
6 Taking a direction. The self as context, process and content. Awareness of the present: ‘here and now’. The brain 
and emotions: managing situations and overwhelming emotional responses.
7 Dare and change: willingness and determination. Self- awareness, assertiveness and self- esteem. Experiential 
expansion exercises: felt sensations. Happiness according to positive psychology. Benefits of physical exercise: 
movement.
At the beginning of each session, time will be taken to briefly go over what was discussed in the previous session and every person’s weekly 
records will be collected and briefly commented on.
ACT, Acceptance and Commitment Therapy.
Table 2 Outline of BATD group treatment sessions
Session Description
1 Participants’ and clinician’s presentation. Collection of information related with areas of activity and interaction 
contexts. Delivery of activity log to obtain an accurate assessment of the patient’s daily activities, which is 
useful for: providing a baseline measure and comparing their progress when their activity level increases later in 
the treatment.
2 Identification of information related to depressive behaviours. Exploration of problematic behaviours and 
identification of patients’ objectives regarding treatment.
3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any 
contexts and interactions that reinforce depressive behaviours. Establishment of short- term, medium- term and 
long- term goals.
4 Explanation of the hypotheses of factors associated with the origins, maintenance and therapeutic change of 
problematic behaviour. In this session, 10 personalised activities are selected according to each person’s own 
needs and desires, without any particular order. With the selected activities, a ranking is then generated that 
goes from the least difficult to the most difficult activity.
5 Once the 10 target activities have been identified, a record is made to track their progress weekly, including the 
number of times they would like to complete the activity in a period of 1 week (the ideal frequency). The number 
of activities varies each week, but they always range between three and five activities.
6 Discussion of what was obtained from the records in general. Exploration of the satisfaction with the activities.
7 Coping abilities. How to approach emotions and reactions to events and responses associated with 
depression. Relationship between avoidance behaviours and maintenance of difficulties.
8 Examination of new behaviours to be incorporated. Discussion about the goals achieved and the barriers to 
maintain the weekly activity plan. Farewell.
BATD, Brief Behavioural Activation Treatment for Depression.
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effectiveness,40 so each therapy will be conducted by at 
least three different therapists. In addition to prior expe-
rience delivering ACT or BATD, all therapists will do a 
3- hour ‘refresher’ training prior to starting the RCT with 
the aim also to assure simultaneous fidelity to the manual 
with flexibility within sessions. Finally, to monitor treat-
ment fidelity within ACT and BATD, research assistants 
will video- tape all sessions. Two independent experts in 
both treatments have been selected for his expertise in 
the delivery of these therapies. They will rate adherence to 
treatment using videotapes of therapy sessions. A random 
sample of tapes, stratified by therapist and therapy session 
will be rated using the instruments described below.
Study measures
All participants will be assessed with a computer- 
administered battery of measures, using the software 
Research Electronic Data Capture (REDCap) (see 
table 3).
Measures for sociodemographic characteristics, clinical 
features and screening
Sociodemographic Questionnaire. Information about gender, 
date of birth, marital status, living arrangements, educa-
tional level, income level and employment status.
Clinical data. Ad hoc interview collecting data about 
history and duration of CLBP and depression symptoms, 
Table 3 Time points at which measures and data are collected
Measures Pre During Post 1- year follow- up
Sociodemographic, clinical and screening measures
  Sociodemographic data (gender, date of birth, marital status) X       
  Clinical data (years of evolution, comorbidities) X       
  PHQ-9 (depression symptoms) X       
  CIDI (diagnosis of depression) X       
  CTQ- SF (childhood trauma) X       
Primary outcome measure
  BPI- IS (pain interference) X   X X
Secondary outcome measures
  NRS (pain intensity) X   X X
  DASS-21 (anxiety, depression and stress) X   X X
  PCS (pain catastrophising) X   X X
Process measures         
  CPAQ-8 (pain acceptance) X   X X
  BADS- SF (behavioural activation for depression) X   X X
Other measures         
  EQ- 5D- 5L (quality of life) X   X X
  CEQ (credibility and expectations regarding treatments) X   X   
  CSRI (medication consumption and service receipt) X     X
  AET (negative effects of psychological treatments)     X   
  PGIC and PSIC (impression of change)     X   
  ACT- FM (fidelity measure)   X X   
  QBAS (fidelity measure)   X X   
  Pain Monitor app   X     
Physiological variables
  Immune- inflammatory markers X   X   
  HPA and vitamin D markers X   X   
  FKBP5 polymorphisms X       
ACT- FM, Acceptance and Commitment Therapy Fidelity Measure; AET, Adverse Effects of Treatments checklist; BADS- SF, Behavioural 
Activation for Depression Scale (short form); BPI- IS, Brief Pain Inventory- Interference Scale; CEQ, Credibility/Expectancy Questionnaire; CIDI, 
Composite International Diagnostic Interview—depression section; CPAQ-8, Chronic Pain Acceptance Questionnaire (8- item version); CSRI, 
Client Service Receipt Inventory; CTQ- SF, Childhood Trauma Questionnaire−Short Form; DASS-21, Depression Anxiety Stress Scales-21; EQ- 
5D- 5L, EuroQoL; HPA, hypothalamic–pituitary–adrenal; NRS, Numerical Pain Rating Scale; PCS, Pain Catastrophising Scale; PGIC, Patient 
Global Impression of Change; PHQ-9, Patient Health Questionnaire; PSIC, Pain Specific Impression of Change; QBAS, Quality of Behavioral 
Activation Scale.
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and family history of medical/mental illness. Information 
regarding comorbidity with other diagnosed physical–psy-
chiatric conditions and the type and dose of current drugs 
will be consulted in medical records.
The Patient Health Questionnaire (PHQ-9).41 42 Each of 
the nine PHQ items corresponds to one of the DSM- IV 
Diagnostic Criterion A symptoms for major depressive 
disorder. Response options are ‘not at all’, ‘several days’, 
‘more than half the days’ and ‘nearly every day’, scored 
as 0, 1, 2 and 3, respectively. In addition, the PHQ-9 has 
a functional impairment question (item 10) that asks 
how much the symptoms they endorse in the first nine 
items interfere with daily functioning. The questionnaire 
can be used algorithmically for the probable diagnosis 
of a depressive disorder, or as a continuous measure of 
scores ranging from 0 to 27, with cut- off points of 5, 10, 
15 and 20, which set the levels of symptoms of depres-
sion as mild, moderate, moderately severe or severe. In 
the present work, if potential participants obtain a score 
≥2 at item 9 (risk of suicide), additional assessment will 
be undertaken to explore the real risk of suicide. The 
telephone- administered version of the PHQ-9 showed 
adequate reliability (α=0.82),43 therefore it seems highly 
recommendable for our telephone- based screening of 
concomitant depression symptomatology.
The Composite International Diagnostic Interview—depres-
sion section (CIDI V.3.0).44 The CIDI is a fully structured 
diagnostic interview developed and validated by the 
WHO to be used with the general population by trained 
lay interviewers. The interview will be used to confirm the 
presence of major depression. The psychometric proper-
ties of the CIDI have been examined extensively and are 
highly sound.44
The Childhood Trauma Questionnaire−Short Form (CTQ- 
SF).45 The CTQ- SF is a 28- item retrospective question-
naire designed to capture five dimensions of childhood 
maltreatment (each scale includes five items): physical 
abuse; emotional abuse; sexual abuse (SA); physical 
neglect and emotional neglect (EN). Additionally, there 
is a three- item minimisation/denial scale. Items are 
scored from 1 to 5 in order to reflect the frequency of 
maltreatment experiences (‘never true’ to ‘very often 
true’). Higher scores indicate greater child abuse and 
neglect. The Spanish CTQ- SF obtained Cronbach’s α 
values ranging from 0.66 for EN to 0.94 for SA.46
Primary outcome measure
The Brief Pain Inventory- Interference Scale (BPI- IS).47 The 
BPI- IS is a seven- item self- report measure that assesses 
the extent to which pain interferes with general activity, 
walking, work outside and inside the home, sleep, mood, 
enjoyment of life and relationships, each rated on a 0 
(‘does not interfere’) to 10 (‘completely interferes’) 
scale. Scoring is done by computing the arithmetic mean 
of all items, such that higher scores indicate greater pain 
interference. A reduction of 1 point on the BPI- IS is 
considered as a clinically meaningful change. The BPI- IS 
is highly recommended as an outcome in clinical trials of 
patients with chronic pain and the psychometric proper-
ties are well- established (α>0.80).48
Secondary outcome measures
The Numeric Rating Scale (NRS).49 The NRS is a unidimen-
sional measure of pain intensity mainly used for adults. 
The most used version is an 11- point numeric scale (a 
horizontal bar or line) with 0 representing ‘no pain’ and 
10 representing ‘worst pain imaginable’. Time frames 
vary between studies. In the present work, respondents 
will be asked to report average pain intensity over the last 
week.
The Depression Anxiety Stress Scales-21 (DASS-21).50 The 
DASS-21 is a self- report measure developed to differen-
tiate between features of depression (low positive affect), 
anxiety (physical arousal) and stress (psychological 
tension/agitation) in clinical and non- clinical samples. In 
addition, the DASS has been validated in clinical chronic 
pain samples.51 Responders are required to indicate the 
presence of a symptom over the previous week. Each item 
is scored from 0 (‘did not apply to me at all over the last 
week’) to 3 (‘applied to me very much or most of the 
time over the past week’). There are seven items on each 
of the three subscales (Depression, Anxiety and Stress). 
Therefore, total scores in each scale can range from 0 to 
21. Higher scores indicate more severe levels of depres-
sion, anxiety and stress. The Spanish version obtained 
adequate internal consistency (0.84, 0.70 and 0.82 for the 
depression, anxiety and stress scales, respectively).52
The Pain Catastrophising Scale (PCS).53 The PCS will be 
used to assess the pain catastrophising thoughts. It is a 
13- item measure that captures three dimensions: rumina-
tion over pain, magnification of pain and helplessness in 
the face of pain symptoms. Each item is answered on a 
rating scale of 5 points (0 = ‘never’, 4 = ‘almost always’). 
Total scores on each scale can range from 0 to 52, with 
higher scores indicating more pain catastrophising 
thoughts. The Spanish PCS has shown good internal 
consistency (α=0.79) and test–retest reliability (r=0.84).54
Process measures
The Chronic Pain Acceptance Questionnaire (CPAQ-8).55 The 
CPAQ-8 is a self- report measure reflecting engagement in 
important activities with pain and willingness to experi-
ence pain. The eight items are rated on a 7- point scale (0= 
‘never true’, 6= ‘always true’). Higher total scores reflect 
greater acceptance. The Spanish CPAQ‐8 has adequate 
internal consistency, a Cronbach α values of 0.75.56
The Behavioural Activation for Depression Scale—short 
form (BADS- SF).57 58 Behavioural activation is conceptual-
ised as a key therapeutic process in BATD. The BADS- SF 
assesses this construct by means of a 9- item scale. Items 
are answered on a Likert scale of 7 points ranging from 
0 (‘not at all’) to 6 (‘completely’). Higher scores indicate 
greater behavioural activation in depressed individuals. 
The BADS- SF has shown adequate internal consistency 
(α=0.82).57
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Other measures
The EuroQoL (version EQ- 5D- 5L).59 The EQ- 5D- 5L is a 
health- related quality of life questionnaire that consists 
of two parts: in the first part, the individual’s difficul-
ties concerning mobility, self- care, pain/discomfort and 
anxiety/depression are evaluated; and in the second 
part, the current state of perceived health is assessed by a 
Visual Analogue Scale (VAS) ranging from 0 to 100. The 
EQ- 5D- 5L scores will be used to calculate the Quality- 
Adjusted Life Years (QALYs) during the follow- up period, 
adjusting the duration of time affected by the health 
outcome by the value of the utility.
The Credibility/Expectancy Questionnaire (CEQ).60 The 
CEQ is a quick and easy to complete measure widely 
used to assess credibility and expectations regarding 
treatments. The CEQ contains six items: three of them 
focused on therapy credibility (the extent to which the treat-
ment appears logical; the extent to which the treatment 
appears useful and the confidence with which the patient 
would recommend the treatment to a friend having the 
same problem) and three items assessing expectations (the 
extent to which the patient thinks an improvement will 
occur; the extent to which the patient feels that therapy 
will help him/her and the extent to which the patient 
feels an improvement will occur). The CEQ has demon-
strated satisfactory psychometric properties.60
The Client Service Receipt Inventory (CSRI).61 The CSRI 
will be used to collect retrospective data on medication 
consumption and service receipt. Regarding medication 
intake, patients are asked to bring their daily medication 
prescriptions and the following information for pain- 
related drugs (ie, analgesics, anti- inflammatories, opioids, 
muscle relaxants, antidepressants) is recorded: the name 
of the drug, the dosage, the total number of prescrip-
tion days and the daily dosage consumed. Concerning 
service receipt, patients are asked about the total visits 
to accident and emergency services, the total number 
of general inpatient hospital admissions, the number of 
diagnostic tests administered and the total visits to health-
care professionals for pain management, including family 
physicians, nurses, social workers, psychologists, psychia-
trists, group psychotherapy and other community health-
care professionals, specifying in each case if these services 
were provided by the public or by the private sector. The 
CSRI will be administered on two occasions: at baseline 
and at 12- month follow- up, both referring to the previous 
12 months. Medical records will be checked to verify the 
accuracy of the collected data.
Ad- hoc measure of Adverse Effects of Treatments. It was 
developed in a previous RCT36 and will be used to check 
the presence of negative effects of ACT and BATD. The 
item reads as follows: Have you experienced, during the course 
of the psychological treatment, any unwanted symptom that you 
think might be directly or indirectly associated with the psycholog-
ical intervention?
The Patient Global Impression of Change (PGIC) and the 
Pain Specific Impression of Change (PSIC).62 Patient impres-
sion of change measures are frequently used as indicators 
of meaningful change in treatments for chronic pain. 
The most frequently used scale is a 7- point numerical 
scale (from 1= ‘Much better’ to 7= ‘Much worse’). The 
PGIC is one item referred to the perception of global 
improvement, whereas the PSIC asks about the impres-
sion of change in more specific domains: physical and 
social functioning, work- related activities, mood and 
pain. These scales will be completed by the participants 
who are assigned to ACT and BATD.
The Acceptance and Commitment Therapy Fidelity Measure 
(ACT- FM).63 The ACT- FM is a recently developed 25- item 
measure that captures four areas: therapist stance, 
open response style, aware response style and engaged 
response style (each split into ACT consistent and ACT 
inconsistent items, making eight sections in all). Items 
are rated on a 4- point scale from 0 (‘behaviour never 
occurred’) to 3 (‘therapist consistently enacts this 
behaviour’).
The Quality of Behavioural Activation Scale (QBAS).64 The 
QBAS is a 14- item scale designed to assess ability in imple-
menting behavioural activation. Items are rated using a 
7- point Likert- type scale with higher scores indicating 
higher implementation quality (total score range 0–96). 
A score of 3 on each item corresponds to satisfactory skill 
in implementing the BA component delineated by that 
item. Preliminary psychometric analysis of this instru-
ment yielded adequate inter- rater reliability (intraclass 
correlation coefficient=0.72).
Ecological momentary assessment (EMA)
Pain severity and other pain- related variables included in 
the study (eg, mood symptoms and health- related quality 
of life, to name some examples) can fluctuate during the 
day and across days depending on many factors, such 
as environmental stressors. Additionally, retrospective 
evaluation is known to be susceptible to memory bias.65 
Retrospective evaluation can lead to overestimation of 
the symptomatology, which can be avoided by frequent 
evaluations of the present symptomatology. Moreover, the 
prospective and repeated evaluation over time substan-
tially improves the accuracy, reliability and quality of 
research.66 While EMA has been difficult for decades 
due to the problems associated with paper diaries, the 
availability of smartphones and the explosion of apps 
is making EMA easiest than ever.67 There is growing 
evidence indicating that well- designed smartphone can 
be very easy to use and well accepted even in relatively old 
pain populations, and compliance rates with daily assess-
ment have been as high as 75%.66 In the present study, we 
will use the Monitor del Dolor (Pain Monitor) app, which 
has been recently validated in an empirical study68 that 
assessed a number of biopsychosocial constructs twice a 
day during 4 weeks. In the present work, we will assess 
daily (twice a day: once in the morning and once in the 
evening, at convenient times) the items listed in table 4 
during the 8- week treatment period.
 o
n
 August 5, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-038107 on 23 July 2020. Downloaded from 
9Sanabria- Mazo JP, et al. BMJ Open 2020;10:e038107. doi:10.1136/bmjopen-2020-038107
Open access
Physiological variables
Immune- inflammatory markers. After drawing the blood, it 
will be allowed to coagulate for a minimum of 30 min at 
room temperature and then centrifuged for 10 min at 
1000 g. The resulting serum will be stored at −80°C during 
the same morning of extraction until it is ready to be anal-
ysed. All samples (pre and post) will be analysed in a single 
analytical batch to reduce inter- assay variability (approx. 
15%). The serum levels of cytokines IL-6, CXCL-8, IL-10, 
TNF-α, IL-1β and high- sensitivity C- reactive protein will 
be evaluated. For the quantification of the cytokines, the 
Milliplex reagents from the company MerckMillipore 
will be used and analysed using a Luminex platform. 
The high sensitivity multiplex kit will be used: Human 
High Sensitivity T Cell, catalogue number: HSTCMAG-
28SPMX11 adapted to the aforementioned cytokines. 
The hs- PCR will be quantified using turbidimetry in an 
Olympus AU5400 auto- analyser.
Hair cortisol and cortisone, blood cortisol, CBG and vitamin 
D. Hair samples will be obtained from the middle- lower 
back area of the head as it is less exposed to environ-
mental conditions such as sunlight, which affect the 
hormone levels in hair and as close as possible to the 
scalp. No products such as gels, lacquers or softeners will 
be used during the 3 days prior to obtaining the sample. 
A strand about 10 mm thick from the posterior vertex 
will be taken, packed in foil to avoid light impact and 
stored at room temperature. For the hormones deter-
mination only the 1 cm of hair closest to the scalp will 
be analysed. The extraction of hormones will be done 
from pre–post samples in the Nutrition and Obesity 
Laboratory of the Biochemistry and Molecular Medi-
cine Department (University of Barcelona, UB), as they 
are obtained. The protocol consists, after hair samples 
weighing, of a previous wash with 5 mL of isopropanol to 
remove accumulated dirt and sweat, detergent residue or 
cosmetic products. Then, hair samples are dried at 37°C 
and minced. Cortisol and cortisone are extracted in 2 mL 
liquid chromatography with tandem mass spectrometry 
(LC–MS) grade methanol and stirring overnight at room 
temperature in the presence of deuterated Cortisol- d4 
and Cortisone- d8 (Sigma Aldrich solution C-113 and 
900170). The methanol is transferred to test tubes and 
evaporated in a dry bath at 50°C under a stream of N2. The 
dried tubes are stored at −20°C until the quantification of 
cortisol and cortisone by LC- MS/MS at the Scientific and 
Technological Centres of the UB (CCiTUB). The levels 
of vitamin D and cortisol in serum will be determined by 
ELISA (DRG EIA-5396, EIA- 1887R and EIA-3647) and 
CBG by RIA125I (IBL KIP1809) in a radioactive facility 
situated at the UB.
Polymorphisms in the FKBP5 gene. A blood sample of 4 mL 
will be collected in a vial with EDTA anticoagulant (BD 
Vacutainer; BD, NJ, USA). Specifically, the analysis of the 
genetic variants of the FKBP5 gene will be carried out in 
the Molecular Genetics Laboratory of the Anthropology 
Unit (UB). The samples will be coded, preserved and the 
DNA will be extracted with the Real Extraction DNA kit 
(Durviz S.L.U., Valencia, Spain). Quality of the DNA will 
be tested using the Nanodrop D1000 (Thermoscientific, 
Wilmington, DE). The genotyping of the five proposed 
SNP polymorphisms in the FKBP5 gene will be carried out 
using TaqMan 5′ exonuclease assay (Applied Biosystems) 
technology at the Scientific and Technological Centres of 
the UB (CCiTUB): rs3800373 (SNP1), rs9296158 (SNP2), 
rs1360780 (SNP3), rs9470080 (SNP4) and rs4713916 
(SNP5). The PCR reaction will be carried out on the ABI 
PRISM 7900HT instrument thermal cycler and geno-
type analysis will be carried out using SDS V.2.1 software 
(Applied Biosystems). For accuracy of genotyping, 15% of 
the samples, randomly selected, will be genotyped twice. 
Finally, the estimation of haplotypes will be conducted 
in order to increase the power to detect genetic associa-
tions.69 Linkage disequilibrium between the five polymor-
phisms in the FKBP5 gene will be examined by pair- wise 
comparisons of r2 and D’ using Haploview V.4.2.70 Estima-
tion of FKBP5 haplotype combination per subject will be 
conducted using a Bayesian approach implemented with 
PHASE software.71
Statistical analysis
The main analysis will compare the effect of the treat-
ments on the primary outcome (pain interference at 
12 months follow- up). All data analyses will be carried out 
Table 4 List of items administered via pain monitor app
Items Morning Evening
Pain intensity X X
Fatigue X X
Perceived control over pain X X
Openness to thoughts and feelings X X
Focused in the present moment X X
Guided by goals and values X X
Perceived competence X X
Activity level X X
Perceived stress X X
Perceived social support X X
Rumination X X
Magnification X X
Helplessness X X
Sleep disturbance X   
Interference with leisure activities X X
Interference with work- related activities X X
Rescue medications X X
The Pain Monitor app informs patients automatically when to 
respond (by default, at 11 AM and 7 PM) using a push notification 
system, but patients can change the assessment times with a 
flexibility of 2 hours from given times. Collected data are stored on 
a secure server at the Jaume I University, Spain. The app and the 
data are stored on different servers with different domain names 
and connected locally only (the server containing the data does not 
have Internet access).69
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following an intention- to- treat (ITT) principle, that is, 
regardless of protocol adherence. Then, we will compute 
analysis of the primary outcome post- treatment and anal-
ysis of the secondary and treatment process outcomes 
at post- treatment and at 12- month follow- up. The anal-
yses will be replicated from a per- protocol approach. 
Multi- level, linear mixed models will be created using 
the restricted maximum likelihood method for the esti-
mation of parameters. The effect sizes will be calculated 
according to Cohen’s d. No interim analysis is planned for 
this RCT. A 5% significance level will be used in all two- 
tailed tests, applying the Benjamini- Hochberg correction 
for multiple comparisons (to reduce the risk of false posi-
tives). For these analyses, we will use SPSS V.24.0.
To examine whether the effects of ACT and BATD 
in addition to usual care on primary and secondary 
outcomes at 12- month follow- up are mediated through 
pre–post changes in pain acceptance (CPAQ-8), and 
behaviour activation (BADS- SF), respectively, we will 
calculate pre–post changes in the total scores of the 
CPAQ-8 and the BADS- SF and pre- follow- up change 
scores in the primary and secondary outcomes. Then, 
bivariate Pearson correlations will be computed between 
the pre–post change in the process variables and the 
pre- follow- up change in the outcomes to detect poten-
tial significant relationships. Finally, we will explore 
the direct and indirect associations between the treat-
ment condition (TAU+ACT vs TAU and TAU +BATD vs 
TAU as independent variable), CPAQ-8 and BADS- SF 
(mediators), and primary and secondary outcomes 
(dependent variables) using path analyses. The direct 
paths between the treatment condition and clinical 
outcomes and the indirect effect path through CPAQ-8, 
and BADS- SF will be tested in all models. Regression 
coefficients (B) of bias- corrected bootstrapped indirect 
effects will be calculated as well as their SEs and 95% 
CIs. Parameters of indirect effects are considered statis-
tically significant when the 95% CI does not include 0. 
The MPlus V.7.4 will be used to compute the mediation 
models.
Regarding analyses of the EMA data, Group 
(TAU+ACT vs TAU+BATD vs TAU), Time (each of the 
EMA measurement points; up to two assessments per day 
× 60 days) and the Group × Time interaction will be the 
primary fixed effects of interest.
Regarding the economic evaluation, when the cost- 
utility of two or more therapeutic options is compared, 
it is necessary to calculate the relationship between the 
costs of each treatment and its consequences in the form 
of QALYs, a measure designed for assessing both quantity 
of life (years) and health- related quality of life (ie, a year 
lived with the maximum quality of life would be trans-
formed into 1 QALY; a year lived with half the maximum 
quality of life would be transformed into 1/2 QALY). 
This relative value will be called the incremental cost- 
utility ratio (ICUR), and it will express the relationship 
between the costs and the effects of one option compared 
with another. The QALYs obtained in the 12 months after 
the start of the treatments will be calculated by the area 
under the curve.
The direct costs will be calculated by adding together 
the costs derived from the medication and the use of the 
health services. The cost of medications will be calcu-
lated by multiplying the price per milligram by the total 
daily dose consumed (in milligrams) and the number of 
days that the treatment is received. The cost arising from 
the use of the health services (primary care, specialist 
and accident and emergency consultations and hospital 
admissions) will be obtained from the eSalud database 
(http://www. oblikue. com/ en/ esalud. html). The indi-
rect costs will be calculated based on the days off work, 
which will be multiplied by the official minimum wage 
during the study period. The effect of the treatments will 
be estimated using ordinary least squares multivariate 
regression, adjusting for the baseline differences between 
groups. In order to manage uncertainty in the sampling 
distribution of the ICUR, non- parametric bootstrapping 
will be applied, with 1000 replications in each compar-
ison. Cost- utility analyses will be conducted with STATA 
V.16.0.
Patient and public involvement
Patients or the public were not involved in the design, or 
conduct, or reporting or dissemination of our research.
ETHICS AND DISSEMINATION
All procedures performed in this study will be in accor-
dance with the 1964 Helsinki declaration and its last 
amendments (seventh revision, adopted by the 64th 
World Medical Association General Assembly, Fortaleza, 
Brazil). Signed informed consent will be obtained from 
all patients once they have been informed of the study 
procedures, potential risks and their right to withdraw 
at any time from the RCT. The FSJD Ethics Committee 
Board evaluated and approved the study protocol in 
September 2019 (PIC-178-19). The Hospital del Mar 
Ethics Committee Board evaluated and approved the 
study protocol in November 2019 (2019/8866/I). Only 
the principal investigator (JVL) will have full access to the 
final trial data set.
Once the RCT is completed, we will publish our results 
in international peer- reviewed biomedical journals and 
present them at national and international confer-
ences. In addition, we will send participating patients 
a short report of our findings. A copy of the report 
will also be sent to Institute of Health Carlos III (main 
funding body). The principal investigator will organise 
an end- of- study knowledge translation seminar. The 
main objective of this activity will be to share the study 
findings with stakeholders in order to discuss how to 
maximise uptake of the findings in patient treatment 
and clinical practice, and to determine future research 
directions.
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DISCUSSION
The present manuscript describes the design and protocol 
of an RCT that aims to assess the efficacy, cost- utility and 
physiological effects of adding ACT or BATD to TAU for 
the management of CLBP and moderate to severe levels 
of depressive symptoms. If the results are strong enough in 
terms of cost- utility, in one or both of the evaluated treat-
ments (ACT and BATD), they could be considered for inclu-
sion in the public healthcare system to treat patients with 
CLBP and depression, and could be used to treat similar 
conditions if such general applicability is demonstrated. 
The fact that these treatments are performed in groups can 
make them more cost- effective, and therefore of interest 
for health managers.72 Additionally, if the results are posi-
tive, these treatments could also be tested in similar chronic 
conditions (eg, fibromyalgia, irritable bowel syndrome, or 
chronic fatigue syndrome) that also frequently present with 
comorbid depression symptoms.
This study has some strengths that should be high-
lighted. The inclusion of a large sample and the inclu-
sion of a comprehensive set of measures will allow us 
to explore important pain- related outcomes and treat-
ment mediators. Our study will both focus on the clin-
ical effects of ACT and BATD as add- on treatments in 
the long- term, and also on the psychological constructs 
and physiological variables that may be involved in the 
changes experienced by patients after treatment. On the 
whole, our study explores genetic, neuroendocrine (HPA 
axis) and immune- inflammatory (cytokines) pathways 
with a combination of technologies which may lead to a 
characterisation of biochemical markers and targets rele-
vant to increase our understanding of both chronic pain 
and depression, new therapeutic interventions to manage 
these disorders, and a better prediction of treatment 
results based on individual variations of these biomarkers 
in the line of personalised medicine. In addition, this 
study will use a smartphone app to monitor the treat-
ments’ effects ecologically, which is a novel approach into 
the pain literature exploring the effectiveness of psycho-
logical interventions.
It is important to mention that we will analyse five 
different polymorphisms in the FKBP5 gene whose 
interest relies on its implication in HPA axis stress 
response regulating glucocorticoid receptor affinity and 
signalling. Previous gene- environment studies have found 
associations between the variability of this gene and early 
trauma with depression73 74 and anxiety.75 Based on these 
findings, our main aim is to explore, for the first time, the 
moderator role of the interaction between FKBP5 gene 
polymorphisms and childhood trauma on the response to 
psychological treatments for chronic pain and depression.
There are some potential limitations that should be 
acknowledged. First, there may be a higher than expected 
dropout rate due to the length of the study (1 year). 
Second, there is a risk that not all recruited patients have 
a smartphone or that completion rates may be unsatis-
factory, so EMA might not be possible or effective for all 
participants. Participants who do not engage will not be 
excluded, but the analyses will be limited to the classical 
assessments. Finally, we have to note the lack of blinding 
of patients and therapists, a typical bias in RCTs of psycho-
logical treatments.
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